lifestyle.thedishh.com

Author: Oncolytics Biotech, Inc.

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

April 7, 2026
Oncolytics Biotech® Completes Domicile Change to the United States

April 1, 2026
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

March 19, 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

March 2, 2026
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

February 24, 2026
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

February 11, 2026